Answers are grounded in this paper and cite their sources.
In this issue of the Journal, two groups of investigators — Bainbridge et al.1 and Maguire et al.2 — describe the first results of separate clinical trials investigating the short-term safety and preliminary efficacy of gene therapy for Leber's congenital amaurosis. Both groups present short-term data (12 months and 5 months, respectively) on three patients with Leber's congenital amaurosis in each study; the patients were enrolled in trials of recombinant adeno-associated viral delivery of the human retinal pigment epithelium-specific 65-kDa protein gene (RPE65), which was administered as a subretinal injection during vitrectomy.Originally described by Leber in 1869, . . .
No takes yet. Share an insight, caveat, or question.
Joan W. Miller (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: